Svein Lien appointed ceo of Biotec Pharmacon

Lien has a financial background and extensive experience at technology and diagnostics businesses

Svein Lien has become chief executive of Norwegian pharmaceutical firm Biotec Pharmacon following the resignation of Lars Viksmoen.

Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.

Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.

You may also like

Ingredients

ArcticZymes receives research grant of US$1.3m

To develop new enzymes for research and diagnostics
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Manufacturing
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Brings decentralised, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
Manufacturing
ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products
Design & Build
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Precision medicine and the fight to revive neuroscience R&D

Precision medicine and the fight to revive neuroscience R&D

In discussion with Dr Kevin Robinson (KSR), Neurvati’s Dr Bruce Leuchter (BL) explores how biology-led development, better diagnosis and rare disease infrastructure could help to unlock stalled neuroscience programmes
Subscribe now